Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jordan A BurdeauDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.ORCID 0000-0002-8835-6997
Briana J K StephensonDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.ORCID 0000-0002-6147-1039
Jorge E ChavarroDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Shruthi MahalingaiahDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Emma V PrestonDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Marie-France HivertDivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
Emily OkenDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Antonia M CalafatDivision of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.ORCID 0000-0002-9796-7482
Sheryl L Rifas-ShimanDivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
Ami R ZotaDepartment of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY 10032, USA.
Tamarra James-ToddDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.ORCID 0000-0003-3589-5169
Funding
Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6M
Prenatal environmental determinants of health in young adulthood: a lifecourse approachR01HD034568 · NICHD · HARVARD PILGRIM HEALTH CARE, INC. · PI Marie-France Hivert, Emily Oken · 1998 to 2026
$20.6M
Training Program in Environmental EpidemiologyT32ES007069 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LADEN, FRANCINE · 1985 to 2024
$13.9M
A lifecourse approach to women's mental health: from fertility to perimenopauseR01HD096032 · NICHD · HARVARD PILGRIM HEALTH CARE, INC. · PI CHAVARRO, JORGE EDUARDO, OKEN, EMILY · 2019 to 2023
$3.6M
Per- and Polyfluoroalkyl substances mixtures and maternal cardiovascular disease risk across the reproductive life courseR01ES031065 · NIEHS · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI JAMES-TODD, TAMARRA M, ZOTA, AMI R · 2020 to 2024
$3.1M
The Training Program in Reproductive, Perinatal, and Pediatric Life Course EpidemiologyT32HD104612 · NICHD · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sonia Hernandez-Diaz, Henning Tiemeier · 2021 to 2026
$2.2M
Maintain and Enrich Resource Infrastructure for Project Viva: a pre-birth cohort with follow up into adolescenceR24ES030894 · NIEHS · HARVARD PILGRIM HEALTH CARE, INC. · PI OKEN, EMILY · 2020 to 2024
$2.0M
National Institutes of Health's National Research Service Award T32 HD 104612NICHD NIH HHS R01 HD034568NICHD NIH HHS R01 HD096032NICHD NIH HHS T32 HD104612NIEHS NIH HHS P30 ES000002NIEHS NIH HHS R01 ES031065NIEHS NIH HHS R24 ES030894NIEHS NIH HHS T32 ES007069NIH HHS P30 ES000002NIH HHS R01ES031065NIH HHS R01HD034568NIH HHS R01HD096032NIH HHS R24ES030894
6 · The paper itself
Abstract
contextEvidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of developing cardiometabolic disease risk factors. Limited research has evaluated associations between PFAS, assessed during pregnancy, a sensitive window for maternal endocrine effects, and long-term maternal adiposity.
objectiveEstimate associations of early pregnancy measures of individual PFAS, and PFAS mixtures, with maternal adiposity in midlife.
methodsWe studied 547 Project Viva participants with measures of early pregnancy (mean gestation 10.0 weeks; mean age 32.5 years) plasma concentrations of 6 PFAS and midlife adiposity outcomes (mean follow-up 17.7 years; mean age 50.7 years), including weight, waist circumference (WC), trunk fat mass (TFM), and total body fat mass (TBFM). We used linear regression and Bayesian Kernel Machine Regression (BKMR).
resultsLinear regression estimated higher midlife weight per doubling of perfluorooctane sulfonate (PFOS) (3.8 kg [95% CI: 1.6, 5.9]) and 2-(N-ethyl-perfluorooctane sulfonamido) acetate (2.3 kg [95% CI: 0.9, 3.7]). BKMR analyses of single PFAS plasma concentrations (comparing the 25th percentile concentration to the 75th percentile) showed a positive association between PFOS and midlife adiposity (weight: 7.7 kg [95% CI: 4.0, 11.5]; TFM: 1.2 kg [95% CI: 0.0, 2.3]; TBFM: 3.0 kg [95% CI: 0.8, 5.2]), but inverse associations with perfluorononanoate (weight: -6.0 kg [95% CI: -8.5, -3.5]; WC: -1.8 cm [95% CI: -3.2, -0.3]; TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.7, -0.3]) and perfluorohexane sulfonate (TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.6, -0.2]). No associations were observed with the overall PFAS mixture.
conclusionSelect PFAS, assessed in pregnancy, may differentially affect maternal midlife adiposity, influencing later-life maternal cardiometabolic health.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. · full record | Socratic